Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Rheumatoid arthritis in 2012

Progress in RA genetics, pathology and therapy

Nature Reviews Rheumatology volume 9, pages 70–72 (2013)Cite this article

Subjects

Developments in our knowledge of the aetiology and pathogenesis of rheumatoid arthritis continued apace in 2012, and several important new advances were reported in the therapy of this disease. Culminating in the approval of a new therapy in the USA, the year offered new insights for clinicians and fresh hope for patients.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Research in 2012 illuminates susceptibility to and aetiology of RA, extends treatment options, and shows that obesity modifies the effects of treatment.

References

  1. Raychaudhuri, S. et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat. Genet. 44, 291–296 (2012).

    Article  CAS  Google Scholar 

  2. Harre, U. et al. Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J. Clin. Invest. 122, 1791–1802 (2012).

    Article  CAS  Google Scholar 

  3. van Vollenhoven, R. F. et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N. Engl. J. Med. 367, 508–519 (2012).

    Article  CAS  Google Scholar 

  4. Fleischmann, R. et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N. Engl. J. Med. 367, 495–507 (2012).

    Article  CAS  Google Scholar 

  5. Ajeganova, S., Andersson, M. L. & Hafström, I. Obesity is associated with worse disease severity in rheumatoid arthritis as well as with co-morbidities—a long-term follow-up from disease onset. Arthritis Care Res. (Hoboken) http://dx.doi.org/10.1002/acr.21710.

  6. Wolfe, F. & Michaud, K. Effect of body mass index on mortality and clinical status in rheumatoid arthritis. Arthritis Care Res. (Hoboken) 64, 1471–1479 (2012).

    Article  Google Scholar 

  7. Stavropoulos-Kalinoglou, A. et al. Anti-tumour necrosis factor α therapy improves insulin sensitivity in normal-weight but not in obese patients with rheumatoid arthritis. Arthritis Res. Ther. 14, R160 (2012).

    Article  CAS  Google Scholar 

  8. de Jong, P. H. et al. Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2011-201162.

  9. Moreland, L. W. et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of early aggressive rheumatoid arthritis trial. Arthritis Rheum. 64, 2824–3285 (2012).

    Article  CAS  Google Scholar 

  10. van Vollenhoven, R. F. et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet 379, 1712–1720 (2012).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Karolinska Institute, Karolinska University Hospital, Solna Building D1:00, Stockholm, SE-17176, Sweden

    Ronald F. van Vollenhoven

Authors
  1. Ronald F. van Vollenhoven
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

R. F. van Vollenhoven declares that he has received research funding grants and speakers honoraria from Abbott, Bristol-Myers Squibb, GlaxoSmithKline, MSD (Merck), Pfizer, Roche, and UCB Pharma.

Rights and permissions

Reprints and permissions

About this article

Cite this article

van Vollenhoven, R. Progress in RA genetics, pathology and therapy. Nat Rev Rheumatol 9, 70–72 (2013). https://doi.org/10.1038/nrrheum.2012.232

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrrheum.2012.232

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing